Google and Harvard team up against COVID

Pandemic forecasting models aren’t hard to find of late, but a new one combines epidemiological expertise from a top-three medical school with AI knowhow from one of big tech’s biggest.

Google Cloud announced its linkup with Harvard’s Global Health Institute Aug. 3, saying the duo would offer free, AI-powered COVID forecasting over the next 14 days to public health officials, frontline healthcare workers and others engaged in the battle.

The system’s algorithms have been trained on public data available from various sources, including Johns Hopkins, the U.S. Census Bureau and Descartes Lab, according to Google.

The model predicts outbreak ebbs and flows on a county-by-county basis such that hospitals, for example, can use it to help make plans for PPE, staffing and scheduling.

Meanwhile state and county health departments can consider its scenarios when strategizing on COVID testing and resource allocations.

Providing accurate, timely predictions of cases, infections, hospitalizations and deaths to both policy makers and the general public “will enhance our ability to understand and respond to the rapidly evolving COVID-19 pandemic,” Thomas Tsai, MD, MPH, of Harvard’s T.H. Chan School of Public Health says in the announcement.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.